In vitro and in vivo models have demonstrated a decrease in PXR and FXR signaling in IBD, with a concomitant improvement in intestinal inflammatory lesions with PXR and FXR agonism9,10,20,36. Here, NR1I2 is linked to inflammatory bowel disease.